# The FDA wants to pull its approval of a drug. It’s not so easy.

- URL: https://talkfuse.com/story/the-fda-wants-to-pull-its-approval-of-a-drug-its-not-so-easy/
- Published: 2026-10-31T11:02:34+00:00
- Updated: 2026-10-31T12:03:50+00:00
- Original publisher: Ars Technica
- Original article: https://arstechnica.com/science/2026/10/the-fda-wants-to-pull-its-approval-of-a-drug-its-not-so-easy/
- Topics: Health, Medicine, Research, Science

## Key points

- FDA seeks to withdraw Tavneos over trial data and safety concerns.
- Amgen says the treatment should remain available.
- The drug’s US future remains undecided.

## Summary

The US Food and Drug Administration is seeking to withdraw Tavneos, a treatment for a rare form of vasculitis, after concluding that the pivotal trial may have involved manipulated data and that the drug lacks substantial evidence of effectiveness. The dispute matters because patients and some doctors regard it as a useful option, while the drug has been linked to serious liver injuries and costs about $220,000 a year.

The FDA approved Tavneos in 2021 after an advisory committee narrowly recommended approval, despite concerns about the trial’s design and uncertain results. Amgen, which acquired the drug’s developer ChemoCentryx, argues that the total evidence supports keeping it available; meanwhile, the trial paper has been retracted and the drug is being removed in Europe and the UK. US regulators still have to decide its fate, amid wider questions about how drug trial data are checked and how effectiveness is established.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.